Skip Navigation



Journal of the National Cancer Institute Advance Access published online on July 29, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn286
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/15/1050    most recent
djn286v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sinha, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinha, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Gene Testing To Tailor Breast Cancer Therapy Has Arrived—Is It Ready for the Clinic?

Gunjan Sinha

The first 150 words of the full text of this article appear below.

To genotype or not? The question is not as profound as Hamlet's, but for oncologists who treat breast cancer, the answer is almost as open to interpretation.

Some studies suggest that women with variant forms of the cytochrome P450 2D6 (CYP2D6) gene may not respond well to tamoxifen—the standard therapy in postmenopausal women with estrogen receptor–positive breast cancer. Other studies, however, have found no such relationship.

In Europe, the conflicting results have prompted caution. CYP2D6 genotyping is not yet offered to patients there. In the U.S., oncologists are split on the issue. Some already offer selected patients the gene test, whereas others think that the science is too premature.

"This falls into the category of legitimate differences in opinion," said Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center in Ann Arbor. Hayes is a member of the Consortium on . . . [Full Text of this Article]

Evidence

In the Clinic

More Data on the Way


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?